Heart & Lung: The Journal of Acute and Critical Care
Volume 37, Issue 2 , Pages 153-156 , March 2008

Adult respiratory distress syndrome after treatment with pegylated interferon α-2a and ribavirin

  • Edmond Vartany, MD

      Affiliations

    • Pulmonary and Critical Care Medicine, Norwalk Hospital, Norwalk, Conn
    • ,
  • Cary A. Caldwell, MD

      Affiliations

    • Division of Gastroenterology, Yale University School of Medicine, New Haven, Conn
    • ,
  • Terence K. Trow, MD

      Affiliations

    • Pulmonary Hypertension Center, Division of Internal Medicine, Section of Pulmonary and Critical Care, Yale University School of Medicine, New Haven, Conn.
    • Corresponding Author InformationReprint requests: Terence K. Trow, MD, Pulmonary Hypertension Center, Division of Internal Medicine, Section of Pulmonary and Critical Care, Yale University School of Medicine, 333 Cedar Street, LCI 105D, PO Box 208057, New Haven, CT 06520-8057.

References 

  1. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(suppl 1):112S–121S
  2. Ogata K, Toshihiko K, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest. 1994;106:612–614
  3. Hoffman SD, Hammadeh R, Shah N. Eosinophilic pneumonitis secondary to pegylated interferon alpha-2b and/or ribavirin therapy. Am J Gastroenterol. 2003;98:S152
  4. Chin K, Tabata C, Satake N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest. 1994;105:939–942
  5. Nouri K, Valor R, Rodriquez FM, Kerdel FA. Interferon alfa-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35:269–270
  6. Ishizaki T, Sasaki F, Ameshima S, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J. 1996;9:2691–2696
  7. Wolf Y, Haddad R, Jossipov J, Werbin N. Alpha-interferon induced severe pneumonitis. J Toxicol Clin Toxicol. 1997;35:113–114
  8. Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci. 2001;322:233–235
  9. Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol. 2002;97:2432–2440
  10. Abi-Nassif S, Mark EJ, Fogen RB, Hallisey RK. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest. 2003;124:406–410
  11. Hoffman RM, Jung MC, Motz R, et al. Sarcoidosis associated with interferon alpha therapy for chronic hepatitis C. J Hepatol. 1998;28:1058–1063
  12. Pietropaoli A, Modrak J, Utell M. Interferon-alpha therapy associated with the development of sarcoidosis. Chest. 1999;116:569–572
  13. Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C. Arch Dermatol. 2005;141:865–868
  14. Takeda A, Ikegame K, Kimura Y, Ogawa H, Kanazawa S, Nakamura H. Pleural effusion during interferon treatment for chronic hepatitis C. Hepatogastoenterol. 2000;47:1431–1435
  15. Bini EJ, Weinshel EH. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Mayo Clin Proc. 1999;74:367–370
  16. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med. 1999;341:556–562
  17. McHutchison JG, Gordon SC, Schiff ER, et al. Hepatitis Interventional Therapy Group Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492
  18. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672
  19. Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  20. Schiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?. Curr Gastroenterol Rep. 2001;3:30–37
  21. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  22. The IDEAL study, Individualized Dosing Efficacy vs. flat dosing to Assess optimaL pegylated interferon. Available at: http://www.idealstudy.com.
  23. Product information: PEG-Intron ®, peginterferon alpha2b. Kenilworth, NJ: Schering Corporation; 2001;

PII: S0147-9563(07)00178-1

doi: 10.1016/j.hrtlng.2007.10.002

Heart & Lung: The Journal of Acute and Critical Care
Volume 37, Issue 2 , Pages 153-156 , March 2008

Article Tools

* Image Usage & Resolution